Aurobindo Pharma Ltd (AUROPHARMA)
Healthcare · Pharmaceuticals · NSE · Updated 1 October 2026
₹1,666.5↑ 53.3% (1Y)
🎯 Key Takeaways
- Revenue grew 3.4% QoQ to ₹9,150 in Q1FY27.
- Market Cap
- ₹95,887
- P/E Ratio
- 26.0
- P/B Ratio
- 2.53
- ROE
- 9.8%
- ROCE
- 12.8%
- Debt/Equity
- 0.20
- Div Yield
- 0.24%
- Promoter
- 51.9%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 8,286 | 8,646 | 8,853 | 9,150 |
| Operating Profit | 1,249 | 1,309 | 1,274 | 1,394 |
| OPM % | 15.1% | 15.1% | 14.4% | 15.2% |
| Net Profit | 848 | 910 | 921 | 1,032 |
| EPS | ₹14.61 | ₹15.67 | ₹15.86 | ₹17.86 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 58 | 58 | 58 | 58 |
| Reserves | 32,595 | 30,820 | 37,833 | 34,983 |
| Borrowings | 8,263 | 8,427 | 7,676 | 7,795 |
| Total Liabilities | 49,785 | 48,094 | 58,502 | 52,546 |
| Fixed Assets | 12,189 | 11,428 | 19,611 | 13,281 |
| Investments | 252 | 325 | 1,051 | 268 |
| Total Assets | 49,785 | 48,094 | 58,502 | 52,546 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +5,526 |
| Investing | -3,459 |
| Financing | -1,269 |
| Net Cash Flow | +799 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 51.8% | 51.8% | 51.8% | 51.9% |
| FII | 14.2% | 13.9% | 15.2% | 16.4% |
| DII | 27.6% | 27.7% | 25.9% | 25.1% |
| Public | 5.3% | 5.4% | 5.7% | 5.4% |
| # Shareholders | 2,47,662 | 2,36,859 | 2,41,298 | 2,39,073 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Corporate Action2026-10-01Aurobindo Pharma announced that its subsidiary Apitoria acquired 100% of A1 Biochem Labs, but Dr. Rajendra Gadikota, former promoter, now holds a 20% …
- 🔴 Announcement2026-09-30Aurobindo Pharma's subsidiary Acrotech Biopharma launched ADQUEY™ (difamilast 1% ointment), a non-steroidal topical PDE4 inhibitor for atopic dermatit…
- 🔴 Announcement2026-09-29Aurobindo Pharma disclosed a GST appellate order confirming reversal of Rs. 2.56 crore excess input tax credit claim for FY 2020-21, including Rs. 1.7…
- Announcement2026-09-24Aurobindo Pharma announced that its trading window will close on October 1, 2026, for all designated persons until 48 hours after the unaudited Q2 res…
- 🔴 Announcement2026-09-21Aurobindo Pharma announced its participation in a JP Morgan Healthcare Trip investor meeting in Hyderabad on September 24, 2026, from 2:30 to 3:30 PM …
- 🔴 Announcement2026-09-15Aurobindo Pharma announced the completion of a US FDA inspection at its Apitoria Pharma subsidiary's Unit-II facility in Telangana, which concluded wi…
- 🔴 Announcement2026-09-15Aurobindo Pharma announced USFDA final approval for its first metered-dose inhaler, Beclomethasone Dipropionate HFA aerosol in 40 mcg and 80 mcg stren…
- 🔴 Corporate Action2026-09-12Aurobindo Pharma announced its step-down subsidiary A1 Biochem Labs (India) acquired 100% of newly incorporated A1 Biochem USA Inc by subscribing to 1…
- 🔴 Announcement2026-09-11Aurobindo Pharma announced its participation in a J. P. Morgan investor conference on September 22, 2026, in Mumbai, offering one-on-one and group mee…
- 🔴 Announcement2026-09-11Aurobindo Pharma announced its participation in the Kotak Healthcare Forum investor meeting on September 18, 2026, in Mumbai, offering one-on-one and …
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AUROPHARMA files new disclosures
Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AUROPHARMA — FreeFree account · 2 AI queries/day